pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,856 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1852Endpoints1437Fierce Biotech753BioSpace741BioPharma Dive544raps246onclive165fda recalls
therapy area
allOncology12816Rare Disease3320Immunology2978Cardiology2841Hematology2280Pulmonology2228
  • FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancers
    The U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
    BioPharma Dive · 6h agoApprovalPositive↗ source
  • Isomorphic Labs lands record $5 billion Series C, marking biggest private biotech raise ever
    Isomorphic Labs, a Google-backed biotech company, announced a $5 billion Series C financing round. The round, completed just six months after a $2.1 billion raise, is the largest private capital r…
    Endpoints · 7h agoDealPositive↗ source
← prev
page 1 of 235
next →
118
fda medwatch113
globenewswire health73
fda press61
Vaccines1839
Psychiatry & CNS1229
Ophthalmology1128
Endocrinology & Metabolism803
Pain788
Nephrology781
  • Isomorphic Labs raises record $5 billion in Series C, doubling its May funding
    Isomorphic Labs, an AI-driven drug design company, announced a $5 billion Series C financing, the largest private biotech raise ever and more than double its $2.1 billion Series B from May. The ro…
    BioSpace · 7h agoDealPositive↗ source
  • Vertex awaits FDA decision on povetacicept for IgA nephropathy, analysts expect approval
    Vertex Pharmaceuticals is awaiting an FDA ruling this month on its investigational drug povetacicept, being evaluated for the treatment of IgA nephropathy. Analysts, including Myles Minter of Will…
    BioSpace · 8h agoRegulatoryPositive↗ source
  • Sellas cancer vaccine cuts death risk by 41% in late-stage AML trial
    Sellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
    BioSpace · 9h agoPositive readoutPositive↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 11h agoApprovalPositive↗ source
  • Isomorphic Labs secures $5 billion Series C, doubling its recent $2.1 billion raise
    Isomorphic Labs, an AI‑driven drug discovery startup spun out of DeepMind, announced a $5 billion Series C financing, marking its second multibillion‑dollar round within six months. The funding fo…
    Fierce Biotech · 15h agoDealPositive↗ source
  • Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugs
    Eli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
    Fierce Biotech · 20h agoDealPositive↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 3h agoApprovalPositive↗ source
  • AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trial
    AriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…
    BioSpace · 9h agoPositive readoutPositive↗ source
  • FDA approves Roche's new breast cancer drug, poised to become its top-selling product
    The U.S. Food and Drug Administration has granted approval to a new breast cancer therapy developed by Roche. This clearance paves the way for the drug's market launch. Roche says the medication c…
    STAT · 9h agoApprovalPositive↗ source
  • Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trial
    Sellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
    STAT · 11h agoPositive readoutPositive↗ source
  • Beren Therapeutics secures FDA approval for Lembaz to treat infantile-onset Niemann-Pick disease type C
    Beren Therapeutics announced that the U.S. Food and Drug Administration has approved its drug Lembaz for the treatment of infantile‑onset Niemann‑Pick disease type C, a rare and severe pediatric co…
    Endpoints · 3h agoApprovalPositive↗ source
  • Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-S
    Sellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
    Endpoints · 5h agoPositive readoutPositive↗ source
  • FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefit
    The FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
    Fierce Biotech · 7h agoCRLNegative↗ source
  • Genetix Biotherapeutics reports $327M YTD sales and projects $500M full-year revenue, marking profitability
    Genetix Biotherapeutics, the former bluebird bio, announced that it has become profitable, reporting $327 million in U.S. net sales year‑to‑date and forecasting total 2026 sales of about $500 milli…
    BioSpace · 11h agoEarningsPositive↗ source
  • Capsida proposes new monkey testing framework after fatal gene therapy trial for brain disease
    Researchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…
    STAT · 14h agoNegative readoutNegative↗ source
  • FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimab
    The U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
    Endpoints · 3h agoRegulatoryNegative↗ source
  • HHS finalizes HIPAA privacy rule update to boost patient access to medical records
    The Department of Health and Human Services announced a final rule change to the HIPAA privacy regulations, marking the first major revision in nearly six years. The updates are designed to simpli…
    STAT · 3h agoRegulatoryPositive↗ source
  • GOP and MAHA leaders dispute FDA nominee Heidi Overton's vaping policy record
    Washington officials are locked in a public dispute over the nomination of Heidi Overton to lead the Food and Drug Administration. The controversy highlights growing divisions within the Republican…
    STAT · 5h agoRegulatoryNegative↗ source
  • AI drugmaker Isomorphic Labs raises $5 billion in Series C round
    Isomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…
    BioPharma Dive · 7h agoDealPositive↗ source
  • Priavoid's Alzheimer's pill PRI-002 fails Phase 2 trial
    German biotech startup Priavoid has been developing a small-molecule pill intended to break up amyloid protein clumps in the brains of Alzheimer's patients. The company recently reported results f…
    Endpoints · 8h agoNegative readoutNegative↗ source
  • Mount Sinai researchers map enzyme structure linked to rare metabolic disorder GA1
    Researchers at Icahn School of Medicine at Mount Sinai have determined the crystal structure of an upstream enzyme involved in glutaric aciduria type 1 (GA1), a rare neuro‑metabolic disease. GA1 r…
    Fierce Biotech · 10h agoPositive readoutPositive↗ source
  • Marrow Therapeutics raises $173M to develop bone-marrow-targeted gene therapies for blood disorders
    Marrow Therapeutics announced a $173 million financing round, combining a $53 million Series A led by founder Scion Life Sciences and venBio with a $120 million Series B led by OrbiMed. The compan…
    BioSpace · 11h agoDealPositive↗ source
  • Marrow Therapeutics secures $173 million to advance siRNA therapy for sickle cell, targeting CRISPR competition
    Marrow Therapeutics announced a $173 million financing round to fund development of its siRNA drug aimed at treating sickle cell disease. The funding comes after FDA approval of two gene therapies…
    Endpoints · 11h agoDealPositive↗ source